Pakistan's AI-Powered News
Four NASA Artemis II astronauts, Victor Glover, Reid Wiseman, Christina Koch, and Canadian astronaut Jeremy Hansen, are preparing for a high-risk "fireball" re-entry into Earth's atmosphere on Friday evening after an unprecedented mission to the far side of the moon. During their first press conference from space on Wednesday, the crew spoke of their emotions and the challenges of re-entering at speeds up to 23,839 mph, testing the Orion capsule's heatshield. This mission is a crucial part of the multibillion-dollar Artemis program, which aims to return humans to the moon by 2028, establish a long-term US lunar presence, and pave the way for future Mars missions, with the current crew seeing themselves as passing a baton to subsequent missions like Artemis III.
Scientists have discovered that variations in two specific genes may explain why weight-loss jabs, particularly GLP1 medicines, work differently for individuals. Analyzing data from almost 28,000 patients, researchers found these genetic differences in gut hormone pathways, which regulate appetite and digestion. These variations can account for different weight-loss outcomes or side effects experienced by patients. This significant finding offers a genetic basis for the varying efficacy of current obesity treatments. Ultimately, understanding these gene variations could lead to more personalized and improved therapeutic strategies for managing obesity.
Nasa's Artemis II astronauts have shared their overwhelming emotions while on their journey home after successfully soaring past the moon. The crew worked in pairs at the Orion capsule windows to capture eagerly awaited images, including detailed photographs of impact craters, cracks, and ridges on the lunar surface. Among their significant captures are images of the Earth rising from behind the moon, a solar eclipse, and parts of the 590-mile wide Orientale impact basin that had never before been observed with the naked eye. This mission marks a crucial step in lunar exploration, providing new visual data and paving the way for future endeavors.
The Artemis II crew, comprising US astronauts Reid Wiseman, Christina Koch, and Victor Glover, along with Canadian Jeremy Hansen, captured a historic 'Earthset' photo on their return journey after a record-breaking lunar flyby. This image, showing Earth dipping below the Moon’s horizon, is a deliberate homage to the iconic 'Earthrise' photo taken by Apollo 8 astronaut Bill Anders in 1968, which captivated the public. The mission is a critical step in NASA's broader program aiming for a Moon landing in 2028, with the crew having already reported vivid details of the lunar surface and witnessed a solar eclipse. Following their successful flyby, President Donald Trump and NASA administrator Jared Isaacman congratulated the astronauts, who are due for splashdown in the Pacific off California late Friday.
The Artemis II crew has successfully completed a historic journey, travelling further from Earth than any humans before. This mission marks Nasa's first crewed voyage to the Moon in over five decades, signifying a major milestone in human space exploration. The crew is now heading for home after achieving this unprecedented distance, demonstrating the capabilities of modern spaceflight. The mission's success is crucial for validating technologies and procedures for future lunar endeavors, paving the way for eventual human landings on the Moon and deeper space exploration.
A new study published in the journal Science highlights significant parallels between cancers in cats and humans, suggesting felines could offer crucial insights for new treatments. Co-authored by Louise van der Weyden of the British Wellcome Sanger Institute, the research analyzed nearly 500 domestic cat tumor samples across 13 cancer types. The team found notable genetic similarities, particularly in breast cancer, where the aggressive FBXW7 gene mutation was present in over half of feline mammary tumors. This mutation, while rare in humans, is similarly aggressive when it occurs. The discovery is vital because the high prevalence of this specific mutation in cats could facilitate broader testing of targeted treatments in veterinary clinics, offering a pathway for therapies that are difficult to trial in humans due to the small number of affected patients.
